Welcome to our dedicated page for ASP Isotopes SEC filings (Ticker: ASPI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ASP Isotopes Inc. (NASDAQ: ASPI) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on ASP Isotopes’ activities as a development stage advanced materials company focused on isotope enrichment technologies, as well as the work of its subsidiaries in nuclear fuels, helium, and related areas.
Through current reports on Form 8-K, ASP Isotopes discloses material events such as the closing of its acquisition of Renergen Limited, a helium and liquefied natural gas producer with operations at the Virginia Gas Project in South Africa. Other 8-K filings describe regulatory approvals for that transaction, private placements of convertible notes issued by its subsidiary Quantum Leap Energy LLC to fund laser enrichment production facilities, and confidential submission of a draft registration statement for a proposed initial public offering of Quantum Leap Energy’s Class A common stock.
The company’s 8-K filings also cover regulatory engagement in the United Kingdom by Quantum Leap Energy Ltd regarding potential High-Assay Low Enriched Uranium (HALEU) production, as well as the acquisition of assets from One 30 Seven Inc. to develop Creber Units for processing water-soluble nuclear waste. These documents provide formal descriptions of transaction terms, use of proceeds, conversion mechanics for notes, and related risk and disclosure language.
ASP Isotopes’ definitive proxy statement on Schedule 14A outlines governance matters, including the annual meeting agenda, director elections, auditor ratification, and voting procedures. The proxy materials also describe the company’s status as an emerging growth company and provide information on its capital structure and shareholder voting rights.
On Stock Titan, investors can use AI-powered tools to read summaries of these filings, quickly identify key sections, and navigate to specific topics such as capital raises, acquisitions, nuclear fuel cycle initiatives, or governance changes. Real-time updates from EDGAR ensure that new 8-Ks, proxy statements, and other relevant filings for ASPI are available as they are published, helping users follow how ASP Isotopes documents its strategic transactions, financing activities, and regulatory developments.
Todd Wider, a director of ASP Isotopes Inc. (ASPI), executed equity transactions on 09/14/2025 and 09/15/2025. He acquired 96,000 shares through exercise of stock options with a conversion/exercise price of $2, and the reported ownership following that transaction was 806,230 shares. The filing also reports 21,892 shares withheld to satisfy option exercise-related obligations at an average price of $8.77, and a sale of 74,108 shares on 09/15/2025 at a weighted average price of $8.7551, leaving beneficial ownership of 710,230 shares after the reported transactions.
ASP Isotopes (ASPI) announced a leadership transition. Effective October 1, 2025, founder Paul Mann became Executive Chairman and began a temporary leave from Chief Executive Officer duties for health reasons. The Board appointed Chief Operating Officer Robert Ainscow as Interim CEO (principal executive officer) in addition to his current role.
Mr. Mann will guide strategy and support senior management alongside the Board, while Mr. Ainscow will manage CEO direct reports and external communications. The company made no new employment arrangements for Robert Ainscow. The filing notes Robert is the brother of Donald Ainscow, EVP, General Counsel and Secretary, whose compensation includes a base salary of $425,000 and an initial grant of 400,000 shares vesting over four years.
ASP Isotopes Inc. reported that it has received a purchase order for enriched Barium-137 from a U.S.-based customer. This order relates to the company’s specialized isotope products and reflects commercial demand from a domestic buyer.
The company communicated this development through a press release dated September 30, 2025, which is included as an exhibit to this report for investors seeking additional operational detail.
ASP Isotopes Inc. filed a Form 8-K to report that it issued a press release on September 29, 2025 announcing changes to the executive management teams of ASP Isotopes Inc. and its subsidiary, Quantum Leap Energy LLC, effective October 1, 2025. The press release describing these leadership changes is included as Exhibit 99.1 and incorporated by reference, except for its third through seventh paragraphs.
ASP Isotopes Inc. reported that its wholly owned subsidiary, Quantum Leap Energy LLC (QLE), has become the controlling shareholder of Skyline Builders Group Holding Limited (SKBL), a Cayman Islands company listed on Nasdaq under “SKBL”. QLE plans to use SKBL to pursue acquisitions of critical materials supply-chain assets that it believes are important for U.S. security and QLE’s long-term growth.
On August 27, 2025, QLE bought all 1,995,000 Class B Ordinary Shares of SKBL from the prior controller for $1,000,000. Each Class B share carries 20 votes, compared with one vote for each Class A share. On August 29, 2025, SKBL completed a Private Placement, issuing 1,359,314 Class A shares plus multiple series of warrants and receiving $17,775,000 in gross proceeds. QLE invested $1,500,000 for Class A shares and warrants, while about $7,000,000 of the proceeds were used to retire 18,500,000 Class A shares held by the former controlling shareholder.
After these steps, QLE holds 79.14% of the aggregate voting power of SKBL and therefore controls the company. ASP Isotopes’ Chairman and CEO, Paul Mann, separately invested $2,500,000 personally in SKBL shares and warrants, subject to a 4.99% beneficial ownership cap on warrant exercises.
ASP Isotopes Inc. has extended the deadline to complete its planned acquisition of Renergen Limited, giving more time to meet closing conditions. Under the proposed South African scheme of arrangement, Renergen shareholders would receive 0.09196 new ASP Isotopes shares for each Renergen share held on the record date.
The longstop date has been moved from September 30, 2025 to November 28, 2025 to obtain remaining regulatory approval and third-party consents. Implementation of the scheme still depends on approval from the Financial Surveillance Department of the South African Reserve Bank, and both companies continue to work toward timely approval.
Robert Ainscow, Chief Operating Officer of ASP Isotopes Inc. (ASPI), reported multiple transactions on September 8-9, 2025. On 09/08/2025 he executed "sell to cover" sales under a Rule 10b5-1 plan totaling 8,438 shares at a weighted average price of $8.5263 to cover tax withholding from vested restricted stock. On 09/09/2025 he was granted or exercised employee stock options: option grants/exercises include 150,000 options at $0.25, 12,000 options at $2, and 135,000 options at $2, increasing beneficial ownership by option awards to positions listed. Net-share settlements of option exercises resulted in withholding of 4,396, 2,813, and 31,652 shares. After the reported transactions the filing person beneficially owned 1,669,693 shares.
Insider transactions by Paul Elliot Mann, CEO, director and 10% owner of ASP Isotopes Inc. (ASPI). The Form 4 reports multiple transactions on September 8-9, 2025. The filing shows sales totaling 447,263 shares disposed through Rule 10b5-1 "sell to cover" and net-share settlements at weighted-average prices reported around $8.14–$8.58. The reporting person also acquired or was issued stock/derivative awards: 216,000 and 1,000,000 employee stock options (exercise price $2) reported as acquired on 09/09/2025. Following these transactions, the reporting person beneficially owned 8,084,191 shares (direct).
The filing discloses that some dispositions were effected under a 10b5-1 trading plan adopted June 9, 2025 to cover tax withholding for vesting restricted stock and that other share withholdings satisfied option exercise obligations. No additional financial results or forward-looking statements are included.
Form 144 filing for ASP Isotopes Inc. (ASPI) reports a proposed sale of 8,438 shares of common stock through Independent Trading Group (ITG) on NASDAQ with an aggregate market value of $69,191.60. The filer acquired 300,000 shares on 09/06/2024 as a restricted stock award from the issuer and indicates the securities were granted as equity compensation. The filing shows 91,913,109 shares outstanding for the issuer and lists the approximate sale date as 09/08/2025. No securities were reported sold by the filer in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Form 144 Notice: The filing discloses a proposed sale of 8,438 shares of common stock of ASP Isotopes Inc. (ASPI) with an aggregate market value of $69,191.60. The securities are to be sold through Independent Trading Group (ITG) Inc., and the sale is identified for 09/08/2025 on the NASDAQ. The filer acquired 300,000 shares on 09/06/2024 as a restricted stock award from the issuer and the acquisition was paid as equity compensation on the same date. The form states there were no sales by the filer in the prior three months and includes the standard signature representation regarding material nonpublic information.